News
While Pfizer said in its petition for mass tort designation that it expected many of the dismissed plaintiffs to refile their ...
5d
Zacks Investment Research on MSNPfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should KnowPfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
2d
24/7 Wall St. on MSN4 Cheap Dividend Stocks Under $50 That Keep Raising PayoutsDividend stocks can set you up for life. But, making the right choice will determine whether you enjoy a steady income or ...
Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...
The dividend remains well supported -- the REIT reported funds from operations ( FFO) per share of $1.05 during the first ...
Science came to life as curious young minds took center stage at the Pfizer School of Science Mobile Experience, a hands-on ...
Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...
Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...
Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...
Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...
The legal action follows a 2024 French study that found that the use of medroxyprogesterone renders a woman five times more likely to develop a meningioma brain tumor.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results